Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the closing of ...

GlobalData analyst Christie Wong said Produodopa’s nearest rival at the moment is Britannia Pharmaceuticals’ continuous subcutaneous infusion of apomorphine delivered using the Apo-go pump ...

Serina's POZ technology is engineered to provide greater control in drug loading and more precision in the rate of release of attached drugs delivered via subcutaneous injection ... About SER-252 (POZ ...

Furthermore, subcutaneous injection of apomorphine is also commonly used to detect the presence of ED in diabetic animal models. This method is based on the central action of apomorphine, which ...

Subcutaneous Opdivo showed comparable effectiveness, safety and tolerability to IV Opdivo in advanced clear cell renal cell ...

In December 2024, the Food and Drug Administration (FDA) approved the PD-1 inhibitor nivolumab (Opvido Qvantig) for use as a subcutaneous injection. Read on to learn more about this new approach ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad ...

AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions ... typically administered as intravenous infusions. Halozyme, developer of rival hyaluronidase ...

The sizes of microplastics ranged from 1 to 62 µm, with a median of about 8.5 µm. HealthDay News — Microplastics appear to be present in filtered solutions used for medical intravenous ...

Merck & Co said on Thursday that it plans to launch a subcutaneously injected version of its blockbuster cancer immunotherapy Keytruda in the U.S. on October 1, and expects to hit peak adoption rates ...

Apellis' C3 inhibitor Empaveli (pegcetacoplan) is also approved for PNH, and is given by subcutaneous infusion, but remains a relatively minor product with sales of less than $25 million in the ...